NASDAQ:IBIO

iBio Q2 2026 Earnings Results & Report

iBio logo
$0.75 +0.04 (+5.86%)
Closing price 04:00 PM Eastern
Extended Trading
$0.76 +0.01 (+1.72%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

iBio missed analyst earnings expectations in its Q2 2026 results, released February 10, 2026. The company reported EPS of -$0.09 versus the -$0.08 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call
4:00 PM ET

iBio EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.08
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 6 quarters

iBio Revenue Results

Actual Revenue
N/A
Expected Revenue
$100 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

iBio Q2 2026 Earnings FAQ

iBio (NASDAQ:IBIO) reported earnings of -$0.09 per share for Q2 2026, missing the consensus estimate of -$0.08. The report was announced on Tuesday, February 10, 2026.

iBio Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Brookline Capital Markets Boosts Earnings Estimates for iBio
See More iBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email.

About iBio

iBio (NASDAQ:IBIO) is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology.

The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development.

iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery. Its programs are in development, and the company’s research priorities may change as its pipeline advances.

View iBio Profile